Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type
- 1 November 2001
- Vol. 92 (9), 2273-2279
- https://doi.org/10.1002/1097-0142(20011101)92:9<2273::aid-cncr1573>3.0.co;2-y
Abstract
BACKGROUND The objective of the current study was to evaluate the ability of serum thyroglobulin mRNA assay in detecting local and distant recurrences in patients who underwent surgery for thyroid carcinoma. METHODS Sixty‐six consecutive patients were studied. One year after surgery, all patients underwent clinical examination and radioiodine scan, and a blood sample was taken for serum thyroglobulin (Tg) immunoassay and for Tg mRNA assay by reverse transcription–polymerase chain reaction (RT‐PCR). RNA was extracted from cells pellet and analyzed by RT‐PCR using specific primers for Tg. RESULTS Thyroglobulin mRNA was detected in 14 (21.2%) patients. Seven of 16 patients with elevated serum thyroglobulin had detectable Tg mRNA. Six of 30 (20%) patients with absent or minimal thyroid bed radioiodine uptake and 7 of 36 (19.4%) patients with significant thyroid bed uptake had detectable Tg mRNA. Among 5 patients with metastases, only 1 (20%) showed circulating Tg mRNA. Overall, the sensitivity, specificity, and accuracy of Tg mRNA assay in predicting the results of the 131I whole‐body scans was 25%, 80%, 25%, respectively. Fourteen of 53 (26.4%) patients with papillary thyroid carcinoma had detectable thyroglobulin mRNA whereas none of the patients with other histologic types did. The sensitivity, specificity, and accuracy of Tg mRNA assay in predicting the results of the 131I whole‐body scans in patients with papillary thyroid carcinoma was 100%, 75%, and 100%, respectively. Of note, the percentage of cases with detectable Tg mRNA was similar among patients who did not receive postoperative 131I and those who had postoperative radioiodine treatment. CONCLUSIONS The current study suggests that the validity of the Tg mRNA assay varies according to the histologic type of thyroid carcinoma and that this assay may play a role in the identification of metastatic disease in the subgroup of patients affected by papillary thyroid carcinoma but does not appear to be sensitive or active enough to direct clinical management. Cancer 2001;92:2273–9. © 2001 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- ReviewDiagnostic Molecular Pathology, 1999
- Strategies for Thyrotropin Use to Monitor Patients with Treated Thyroid CarcinomaThyroid®, 1999
- Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid CarcinomaThe New England Journal of Medicine, 1997
- Detection of circulating thyroid cells in peripheral bloodSurgery, 1996
- Gene Expression of Differentiation- and Dedifferentiation Markers in Normal and Malignant Human Thyroid TissuesExperimental and Clinical Endocrinology & Diabetes, 1992
- Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reactionThe Lancet, 1991
- Demonstration of a heterogeneous transcription pattern of thyroglobulin mRNA in human thyroid tissuesBiochemical and Biophysical Research Communications, 1991
- Structural organization of the 5′ region of the thyroglobulin gene: Evidence for intron loss and “exonization” during evolutionJournal of Molecular Biology, 1987
- Primary structure of human thyroglobulin deduced from the sequence of its 8448-base complementary DNAJBIC Journal of Biological Inorganic Chemistry, 1987